Form 4: Integra LifeSciences Exec Reports Stock Transactions

Harvinder Singh, EVP & President, International, reported multiple acquisitions and dispositions of Integra LifeSciences common stock and restricted stock units.

Summary

• Harvinder Singh, EVP & President, International, of Integra LifeSciences Holdings Corp (IART), reported changes in beneficial ownership.
• On March 10, 2026, Singh acquired 1,216 shares of common stock through the exercise of restricted stock units (RSUs) and disposed of 601 shares for tax withholding at $9.55 per share.
• On March 11, 2026, Singh acquired 18,922 shares of common stock through RSU exercises and disposed of 861 shares and 5,190 shares for tax withholding at $9.61 per share.
• The RSU exercises on March 10, 2026, related to an award that vested 34% on the third anniversary of its March 10, 2023 grant date.
• The RSU exercises on March 11, 2026, related to awards that vested 33% and 100% on the second anniversary of their March 11, 2024 grant date.
• Singh also received a new restricted stock unit award of 60,865 units on March 11, 2026, which will vest 33% on the first and second anniversaries and 34% on the third anniversary of the grant date.
• Following these transactions, Singh's direct beneficial ownership of common stock was 35,422 shares, and derivative securities (RSUs) totaled 63,293 units.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine insider transaction filing, reflecting standard equity compensation vesting and a new grant, which is generally positive for executive retention and alignment. The dispositions are for tax purposes, not open market sales.

Positives

• Acquisition of 1,216 shares and 18,922 shares of common stock through RSU exercises indicates vesting of equity compensation.
• Grant of 60,865 new restricted stock units aligns management incentives with long-term company performance.

Negatives

• Disposal of 601 shares at $9.55, 861 shares at $9.61, and 5,190 shares at $9.61 for tax withholding reduces direct ownership.

Future Outlook

The new RSU grant on March 11, 2026, with a vesting schedule over three years (33% on the first and second anniversaries, 34% on the third), indicates a long-term incentive for the executive, aligning their interests with future company performance.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving equity compensation, are common in the life sciences industry. The vesting and granting of restricted stock units are standard practices to retain and incentivize key executives, aligning their interests with long-term shareholder value.

Comparison to Industry Standards

• This Form 4 filing details routine equity compensation events, which are standard practice across publicly traded companies, including those in the life sciences sector, for executive retention and incentive alignment. It does not contain specific operational or financial results that would allow for direct comparison to specific industry benchmarks or competitor projects.

Stakeholder Impact

• Shareholders: The grant of new RSUs aligns executive interests with long-term shareholder value. Tax-related dispositions are routine and do not signal a lack of confidence.
• Employees: Reflects standard executive compensation practices within the company.

Next Steps

• Future vesting of the newly granted 60,865 restricted stock units on the first, second, and third anniversaries of the March 11, 2026 grant date.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation events for an executive, including the vesting of previously granted restricted stock units and the grant of new ones, along with associated tax withholdings. These transactions are standard practice for executive incentive programs and do not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. The activity reflects ongoing executive alignment with long-term company performance rather than a significant shift in insider sentiment.

Keywords

Integra LifeSciences, IART, Harvinder Singh, Insider Trading, Form 4, Restricted Stock Units, Equity Compensation, Stock Transactions